Regulatory approvals for leflunomide and etanercept has led to various developments in the disease modifying anti-rheumatic drugs (DMARDs) which are used for the treatment of rheumatoid arthritis. Of which leflunomide is a small molecule and non-biological DMARD, whose usage will support in promoting industry growth rate during the study period.
Increasing ageing population and healthcare expenditure will expand the small molecule therapies for rheumatoid arthritis market size over the forecast time line. Rising investments in drug development program and drug discovery will further support in stimulating industry size. Stringent regulations related to efficacy in clinical development may affect the industry revenue generation till 2027.
The small molecule therapies for rheumatoid arthritis market is segmented on the lines of its product and regional. The basis of product the market is segmented into Disease Modifying Anti-Rheumatic Drugs, Non-Steroidal Anti-Inflammatory Drugs, and Corticosteroids. The small molecule therapies for rheumatoid arthritis market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, and Rest of World. Each geographic market is further segmented to provide market revenue for selected countries such as the U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and UCB Pharma are among the major players in the global small molecule therapies for rheumatoid arthritis market share. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Small Molecule Therapies for Rheumatoid Arthritis Market has been segmented as below:
Small Molecule Therapies for Rheumatoid Arthritis Market, By Product
Small Molecule Therapies for Rheumatoid Arthritis Market, By Region
The report covers:
Report scope:
The scope of the report includes a detailed study of small molecule therapies for rheumatoid arthritis market with the reasons given for variations in the growth of the industry in certain regions.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and UCB Pharma. Company profile includes assigning such as company overview, product landscape, financial overview, and recent developments.
The top company reports are intended to provide our buyers with a snapshot of the industry’s most influential players.
Reasons to Buy this Report:
Customization:
We can offer you custom research reports as per client’s special requirements
Below are our New Reports :-
EMEA (Europe, Middle East and Africa) Avian Influenza Vaccines Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Ageing population
4.2.2. Attrition of new small molecule drugs in RA clinical development
4.3. Restraints
4.3.1. High cost of RA drugs
4.3.2. Approval of the drug by regulatory authorities
4.4. Opportunities
4.4.1. Drug discovery and drug development program
4.4.2. Unmet medical need
4.5. Challenges
4.5.1. Need for rheumatologists
4.5.2. Market dominance by TNF-alpha inhibitors
5. Small Molecule Therapies for Rheumatoid Arthritis Market, By Product
5.1. Key Points
5.2. Disease modifying anti-rheumatic drugs
5.3. Non-steroidal anti-inflammatory drugs
5.4. Corticosteroids
6. Competitive Landscape
6.1. Introduction
6.2. Recent Developments
6.2.1. Mergers & Acquisitions
6.2.2. New Product Developments
6.2.3. Portfolio/Production Capacity Expansions
6.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
6.2.5. Others
7. Company Profile
7.1. AbbVie
7.1.1. Company Overview
7.1.2. Product/Service Landscape
7.1.3. Financial Overview
7.1.4. Recent Developments
7.2. Amgen
7.2.1. Company Overview
7.2.2. Product/Service Landscape
7.2.3. Financial Overview
7.2.4. Recent Developments
7.3. Johnson & Johnson
7.3.1. Company Overview
7.3.2. Product/Service Landscape
7.3.3. Financial Overview
7.3.4. Recent Developments
7.4. Novartis
7.4.1. Company Overview
7.4.2. Product/Service Landscape
7.4.3. Financial Overview
7.4.4. Recent Developments
7.5. Pfizer
7.5.1. Company Overview
7.5.2. Product/Service Landscape
7.5.3. Financial Overview
7.5.4. Recent Developments
7.6. UCB Pharma
7.6.1. Company Overview
7.6.2. Product/Service Landscape
7.6.3. Financial Overview
7.6.4. Recent Developments
The Small Molecule Therapies for Rheumatoid Arthritis Market has been segmented as below:
Small Molecule Therapies for Rheumatoid Arthritis Market, By Product
Small Molecule Therapies for Rheumatoid Arthritis Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
